Nima Sharifi

Nima Sharifi

UNVERIFIED PROFILE

Are you Nima Sharifi?   Register this Author

Register author
Nima Sharifi

Nima Sharifi

Publications by authors named "Nima Sharifi"

Are you Nima Sharifi?   Register this Author

82Publications

984Reads

11Profile Views

Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer.

Prostate Cancer Prostatic Dis 2020 Jun 19;23(2):316-323. Epub 2019 Nov 19.

Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-019-0188-4DOI Listing
June 2020

Structure-dependent retention of steroid hormones by common laboratory materials.

J Steroid Biochem Mol Biol 2020 Apr 26;198:105572. Epub 2019 Dec 26.

Genitourinary Malignancies Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsbmb.2019.105572DOI Listing
April 2020

Abiraterone acetate treatment lowers 11-oxygenated androgens.

Eur J Endocrinol 2020 Apr;182(4):413-421

Division of Metabolism, Diabetes, and Endocrinology, Department of Internal Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EJE-19-0905DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096060PMC
April 2020

Androgen hazards with COVID-19.

Endocr Relat Cancer 2020 04 24;27(6):E1-E3. Epub 2020 Apr 24.

Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-20-0133DOI Listing
April 2020

Rapid and structure-specific cellular uptake of selected steroids.

PLoS One 2019 17;14(10):e0224081. Epub 2019 Oct 17.

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0224081PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797172PMC
March 2020

Supraphysiologic Testosterone Solutions for Enzalutamide-resistant Prostate Cancer.

Eur Urol 2020 Feb 31;77(2):156-157. Epub 2019 Jul 31.

Genitourinary Malignancies Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.07.037DOI Listing
February 2020

Sex Hormones and Prostate Cancer.

Annu Rev Med 2020 01 15;71:33-45. Epub 2019 Oct 15.

Genitourinary Malignancies Research Center, Lerner Research Institute, Glickman Urological and Kidney Institute, and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA; email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-med-051418-060357DOI Listing
January 2020

Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis.

Biomaterials 2020 Jan 18;227:119558. Epub 2019 Oct 18.

Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biomaterials.2019.119558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6870877PMC
January 2020

HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond.

Endocrinology 2019 09;160(9):2180-2188

Genitourinary Malignancies Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2019-00366DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736215PMC
September 2019

Functional Silencing of in Prostate Cancer Promotes Disease Progression.

Clin Cancer Res 2019 02 18;25(4):1291-1301. Epub 2018 Sep 18.

State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, P.R. China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377858PMC
February 2019

A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients.

Pharmacol Res 2018 10 22;136:56-61. Epub 2018 Aug 22.

Department of Medical Oncology, Hôpital Cochin, AP-HP, Paris, France; University of Paris Descartes, CARPEM, Paris, France; Cochin Institute, INSERM U1016, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10436618183070
Publisher Site
http://dx.doi.org/10.1016/j.phrs.2018.08.016DOI Listing
October 2018

AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.

Endocrinology 2018 08;159(8):2884-2890

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2018-00283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456955PMC
August 2018

HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.

Nat Rev Urol 2018 Mar 12;15(3):191-196. Epub 2017 Dec 12.

Lerner College of Medicine, Education Institute, the Department of Cancer Biology, Lerner Research Institute, the Department of Urology, Glickman Urological and Kidney Institute, and the Department of Haematology and Oncology, Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland Clinic, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2017.201DOI Listing
March 2018

Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer.

Cell Rep 2018 01;22(3):809-819

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.12.081DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798464PMC
January 2018

Development and validation of a novel LC-MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column.

J Steroid Biochem Mol Biol 2017 09 7;172:231-239. Epub 2016 Apr 7.

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, United States; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States; Department of Chemistry, Cleveland State University, Cleveland, OH, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsbmb.2016.04.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124534PMC
September 2017

Androgen Signaling in Prostate Cancer.

Cold Spring Harb Perspect Med 2017 Sep 1;7(9). Epub 2017 Sep 1.

Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio 44195.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/cshperspect.a030452DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580512PMC
September 2017

Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.

Cell Chem Biol 2017 Jul 22;24(7):825-832.e6. Epub 2017 Jun 22.

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Chemistry, Cleveland State University, Cleveland, OH 44115, USA; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2017.05.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533090PMC
July 2017

Could Steroidal Abiraterone Metabolites Possibly Explain Abiraterone Withdrawal Syndrome?

Eur Urol 2016 11 20;70(5):898-899. Epub 2016 Jun 20.

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.06.013DOI Listing
November 2016

HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.

Lancet Oncol 2016 Oct 27;17(10):1435-1444. Epub 2016 Aug 27.

Department of Cancer Biology, Lerner Research Institute, Cleveland, OH, USA; Department of Urology, Glickman Urological & Kidney Institute, Cleveland, OH, USA; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30227-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135009PMC
October 2016

Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition.

Transl Androl Urol 2016 Aug;5(4):616-9

Deparment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA;; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA;; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tau.2016.05.13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5001982PMC
August 2016

Clinical significance of D4A in prostate cancer therapy with abiraterone.

Cell Cycle 2015 ;14(20):3213-4

a Department of Hematology and Oncology ; Taussig Cancer Institute, Cleveland Clinic ; Cleveland , OH USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2015.1086201DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825540PMC
March 2016

Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.

Nature 2015 Jul 1;523(7560):347-51. Epub 2015 Jun 1.

1] Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA [2] Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA [3] Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature14406DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506215PMC
July 2015

DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis.

Cancer Cell 2015 Jul;28(1):97-113

Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA; Department of Urology, Thomas Jefferson University, Philadelphia, PA 19107, USA; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2015.06.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531387PMC
July 2015

Prostate cancer: CYP17A1 inhibitor failure-lessons for future drug development.

Authors:
Nima Sharifi

Nat Rev Urol 2015 May 31;12(5):245-6. Epub 2015 Mar 31.

Department of Cancer Biology, Lerner Research Institute, 9500 Euclid Avenue, Cleveland Clinic, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2015.66DOI Listing
May 2015

Steroid sidestep: evading androgen ablation by abiraterone.

Authors:
Nima Sharifi

Clin Cancer Res 2015 Mar 28;21(6):1240-2. Epub 2014 Nov 28.

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2899DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359949PMC
March 2015

Androstenedione is the preferred androgen source in hormone refractory prostate cancer--letter.

Clin Cancer Res 2014 Sep;20(18):4971

Division of Metabolism, Diabetes, and Endocrinology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1123DOI Listing
September 2014

The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth.

Oncotarget 2014 Aug;5(15):6425-36

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Graduate Institute of Cancer Biology, China Medical University, Taichung, Taiwan.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171641PMC
http://dx.doi.org/10.18632/oncotarget.2228DOI Listing
August 2014

Steroid receptors aplenty in prostate cancer.

Authors:
Nima Sharifi

N Engl J Med 2014 Mar;370(10):970-1

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMcibr1315706DOI Listing
March 2014

Mechanisms of androgen receptor activation in castration-resistant prostate cancer.

Authors:
Nima Sharifi

Endocrinology 2013 Nov 3;154(11):4010-7. Epub 2013 Sep 3.

Cleveland Clinic, Lerner Research Institute, Cancer Biology, NB40, 9500 Euclid Avenue, Cleveland, Ohio 44195.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2013-1466DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948917PMC
November 2013

A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.

Cell 2013 Aug;154(5):1074-1084

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Division of Hematology/Oncology, Department of Internal Medicine and Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2013.07.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931012PMC
August 2013

Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.

Clin Cancer Res 2013 Jul 7;19(13):3353-9. Epub 2013 Mar 7.

Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-0931DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736095PMC
July 2013

Minireview: Androgen metabolism in castration-resistant prostate cancer.

Authors:
Nima Sharifi

Mol Endocrinol 2013 May 16;27(5):708-14. Epub 2013 Apr 16.

Department of Cancer Biology, Lerner Research Institute, Glickman Urological and Kidney Institute and Taussig Cancer Institute, Cleveland Clinic, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/me.2013-1007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634114PMC
May 2013

Prostate cancer-from steroid transformations to clinical translation.

Nat Rev Urol 2012 12 2;9(12):721-4. Epub 2012 Oct 2.

Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2012.175DOI Listing
December 2012

Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.

Clin Cancer Res 2012 Jul;18(13):3571-9

Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-0908DOI Listing
July 2012

Steroid biosynthesis and prostate cancer.

Steroids 2012 Jun 5;77(7):719-26. Epub 2012 Apr 5.

Division of Hematology/Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0039128X120011
Publisher Site
http://dx.doi.org/10.1016/j.steroids.2012.03.015DOI Listing
June 2012

The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer.

Authors:
Nima Sharifi

J Investig Med 2012 Feb;60(2):504-7

Division of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.

View Article

Download full-text PDF

Source
http://jim.bmj.com/lookup/doi/10.2310/JIM.0b013e31823874a4
Publisher Site
http://dx.doi.org/10.2310/JIM.0b013e31823874a4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262939PMC
February 2012

SOD mimetics: a novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer.

Mol Cancer Ther 2012 Jan 15;11(1):87-97. Epub 2011 Dec 15.

Department of Internal Medicine, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0540DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256291PMC
January 2012

Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.

Proc Natl Acad Sci U S A 2011 Aug 27;108(33):13728-33. Epub 2011 Jul 27.

Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1107898108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3158152PMC
August 2011

An update on androgen deprivation therapy for prostate cancer.

Endocr Relat Cancer 2010 Dec 29;17(4):R305-15. Epub 2010 Oct 29.

Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1677/ERC-10-0187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461824PMC
December 2010

Survivin is not induced by novel taxanes.

Mol Pharm 2010 Dec 7;7(6):2216-23. Epub 2010 Oct 7.

Division of Hematology/Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-8852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/mp100211kDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004127PMC
December 2010

"Getting from here to there"--mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer.

J Investig Med 2010 Dec;58(8):938-44

Divisions of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.231/JIM.0b013e3181ff6bb8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589138PMC
December 2010

3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.

Endocrinology 2010 Aug 9;151(8):3514-20. Epub 2010 Jun 9.

Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2010-0138DOI Listing
August 2010

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Authors:
Nima Sharifi

Expert Opin Investig Drugs 2010 Jul;19(7):837-46

Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2010.494178DOI Listing
July 2010

More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.

BJU Int 2010 Apr 8;105(7):913-6. Epub 2010 Jan 8.

Molecular Pharmacology Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2009.08999.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360027PMC
April 2010

Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function.

Authors:
Nima Sharifi

Anticancer Agents Med Chem 2009 Dec;9(10):1046-51

Division of Hematology/Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187152009789735044DOI Listing
December 2009

Commentary: Antioxidants for cancer: new tricks for an old dog?

Authors:
Nima Sharifi

Oncologist 2009 Mar 5;14(3):213-5. Epub 2009 Mar 5.

Division of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2008-0219DOI Listing
March 2009

Androgen receptor expression in prostate cancer stem cells: is there a conundrum?

Cancer Chemother Pharmacol 2008 Oct 13;62(5):921-3. Epub 2007 Dec 13.

Cancer Stem Cell Section, Laboratory of Cancer Prevention, National Cancer Institute at Frederick, Center for Cancer Research, National Cancer Institute Frederick, Frederick, MD 21702, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-007-0659-5
Publisher Site
http://dx.doi.org/10.1007/s00280-007-0659-5DOI Listing
October 2008

Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer.

Clin Cancer Res 2008 Oct;14(19):6073-80

Cancer Stem Cell Section, Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-08-0591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670581PMC
October 2008

The genetics of castration-resistant prostate cancer: what can the germline tell us?

Clin Cancer Res 2008 Aug;14(15):4691-3

Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-0453DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2698703PMC
August 2008

Secondary hormonal therapy for prostate cancer: what lies on the horizon?

BJU Int 2008 Feb 8;101(3):271-4. Epub 2007 Oct 8.

National Cancer Institute, Medical Oncology Branch, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1464-410X.2007.07236.x
Publisher Site
http://dx.doi.org/10.1111/j.1464-410X.2007.07236.xDOI Listing
February 2008

Transforming growth factor-beta receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate?

J Mol Endocrinol 2007 Nov;39(5):329-32

Cancer Stem Cell Section, Laboratory of Cancer Prevention, National Cancer Institute at Frederick, Center for Cancer Research, Frederick, Maryland 21702, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1677/JME-07-0084DOI Listing
November 2007

Screening for prostate cancer: current status and future prospects.

Am J Med 2007 Sep;120(9):743-5

Medical Oncology Branch, National Cancer Institute, Bethesda, Md, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjmed.2006.12.014DOI Listing
September 2007

Androgen receptor modulation: lessons learned from beyond the prostate.

Cancer Biol Ther 2007 Sep 3;6(9):1358-9. Epub 2007 Aug 3.

Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.6.9.4825DOI Listing
September 2007

A bifunctional colchicinoid that binds to the androgen receptor.

Mol Cancer Ther 2007 Aug;6(8):2328-36

Room 21-81, Cancer Stem Cell Section, Laboratory of Cancer Prevention, National Cancer Institute at Frederick, Building 560, Frederick, MD 21702, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-07-0163DOI Listing
August 2007

TGFBR3 loss and consequences in prostate cancer.

Prostate 2007 Feb;67(3):301-11

Cancer Stem Cell Section, Laboratory of Cancer Prevention, National Cancer Institute at Frederick, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.20526DOI Listing
February 2007

Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy.

Cancer Biol Ther 2006 Aug 28;5(8):901-6. Epub 2006 Aug 28.

Cancer Stem Cell Section, Laboratory of Cancer Prevention, National Cancer Institute at Frederick, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.5.8.2949DOI Listing
August 2006

Perturbations in hypoxia detection: a shared link between hereditary and sporadic tumor formation?

Med Hypotheses 2006 20;66(4):732-5. Epub 2005 Dec 20.

Cytokine Molecular Mechanisms Section, Laboratory of Molecular Immunoregulation, Center for Cancer Research, National Cancer Institute at Frederick, Bldg. 560, Room 21-81, Frederick, MD 21702, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mehy.2005.11.003DOI Listing
June 2006

Androgen receptor as a therapeutic target for androgen independent prostate cancer.

Am J Ther 2006 Mar-Apr;13(2):166-70

Cytokine Molecular Mechanisms Section, Laboratory of Molecular Immunoregulation, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00045391-200603000-00013DOI Listing
May 2006

A retrospective study of the time to clinical endpoints for advanced prostate cancer.

BJU Int 2005 Nov;96(7):985-9

Center for Cancer Research, National Cancer Institute/NIH, 10 Center Drive, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2005.05798.xDOI Listing
November 2005

Androgen deprivation therapy for prostate cancer.

JAMA 2005 Jul;294(2):238-44

Medical Oncology Clinical Research Unit, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.294.2.238DOI Listing
July 2005

Vascular events after acute infection or vaccination.

N Engl J Med 2005 Mar;352(11):1151-3; author reply 1151-3

View Article

Download full-text PDF

Source
March 2005

Gene function far from understood.

Authors:
Nima Sharifi

Mayo Clin Proc 2002 Dec;77(12):1395-6; author reply 1396

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4065/77.12.1395-bDOI Listing
December 2002

Targeted chemotherapy: chronic myelogenous leukemia as a model.

J Mol Med (Berl) 2002 Apr 24;80(4):219-32. Epub 2002 Jan 24.

Department of Medicine, University of Pittsburgh School of Medicine, PA 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00109-001-0305-3DOI Listing
April 2002